Produktdaten von Interferon alpha (IFN alpha) ELISA Kit
Produkt-Kategorie | ELISA Kits |
---|---|
Target-Kategorie | |
Menge | 96 Tests |
Synonyme | B Cell Interferon, IFN-alpha, IFNa, IFNalpha, Interferon-alpha, Leukocyte Interferon, Type I Interferon |
Reaktivität | Hu |
Shipping to | Europe only |
PDF datasheet | Datenblatt ansehen |
Hersteller | PBL Assay Science |
Datenblatt-Auszug
Add. information | Citations: |
---|---|
Anwendung | Performance Characteristics Inter-Assay CV: ≤ 8% Intra-Assay CV: ≤ 8% Spike Recovery: ≥ 90% in Serum Materials Provided:
|
Background | The VeriKine Human Interferon Alpha ELISA Kit has been developed to quantify levels of human IFN-alpha in cell or tissue culture media using a sandwich enzyme linked immunoassay (ELISA). The kit is based on an ELISA with anti-detection antibody conjugated to horseradish peroxidase (HRP). Tetramethyl-benzidine (TMB) is the substrate. The assay is based on the international reference standard for human interferon alpha (Hu-IFN-α) provided by the National Institutes of Health. Interferons (IFNs) are a family of mammalian cytokines produced by a variety of cells in response to viral infection, immunity stimulators and chemical inducers. They exhibit a wide range of biological activities that include antiviral, anti-proliferative and immunomodulatory functions. When IFN interacts with its cognate receptor, a signal is rapidly transmitted within the cell, often producing an antiviral state. The primary signal transduction cascade promoted by type I IFNs is the JAK1-STAT pathway. Activation of this signal transduction pathway leads to increased gene expression including (2’-5’) oligoadenylate synthetases, Mx proteins, and protein kinase R (PKR) that protect the cell from viral infection. Interferon Alpha (IFN-alpha), a type I interferon, was one of the first FDA approved biotherapeutic treatments. Accurate measurement of IFN-alpha in cell or tissue culture media allows evaluation of basic immune responses as well as assessing the potency of Toll-Like Receptor (TLR) agonist-based therapeutics in vitro. |
General Readings |
|
Storage | 2-8°C Expiration Date: One year from date of manufacture Shipping Condition: Wet Ice |
Assaytime | 3.5 h |
Range | 10-500 pg/ml |